{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:16:21Z","timestamp":1758046581835,"version":"3.44.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.pharma.2014.03.001","type":"journal-article","created":{"date-parts":[[2014,5,6]],"date-time":"2014-05-06T07:45:24Z","timestamp":1399362324000},"page":"229-237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["\u00c0 propos des ivacaftor, b\u00e9daquiline, florb\u00e9tapir F18\u00a0et propranolol"],"prefix":"10.1016","volume":"72","author":[{"given":"C.","family":"Monneret","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2012","series-title":"La mucoviscidose et autres canalopathies. Physiologie pathog\u00e9n\u00e9tique","author":"Edelman","key":"10.1016\/j.pharma.2014.03.001_bib0005"},{"key":"10.1016\/j.pharma.2014.03.001_bib0010","first-page":"631","article-title":"Les mutations de la mucoviscidose\u00a0: du g\u00e9notype au phenotype","volume":"10","author":"Ferec","year":"1994","journal-title":"Med Sci"},{"key":"10.1016\/j.pharma.2014.03.001_bib0015","article-title":"Therapeutic update in cystic fibrosis","author":"Durupt","year":"2013","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.pharma.2014.03.001_bib0020","unstructured":"ema.europa.eu\/Find medicine\/Human medicines\/European public assessment reports."},{"issue":"10","key":"10.1016\/j.pharma.2014.03.001_bib0025","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/emmm.201302699","article-title":"Discovery of novel potent (F508-CFTR correctors that target the nucleotide binding domain","volume":"5","author":"Odolczyk","year":"2013","journal-title":"EMBO Mol Med"},{"issue":"3","key":"10.1016\/j.pharma.2014.03.001_bib0030","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/hmg\/ddr496","article-title":"Disruption of cytokeratin-8\u00a0interaction with F508del-CFTR corrects its functional defect","volume":"21","author":"Colas","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharma.2014.03.001_bib0035","first-page":"301","article-title":"Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide","volume":"55","author":"Centers for Disease Control Prevention","year":"2006","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.pharma.2014.03.001_bib0040","first-page":"430","article-title":"Extensively drug-resistant tuberculosis (XDR.TB): recommendations for prevention and control","volume":"81","author":"World Health Organization (WHO)","year":"2006","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.pharma.2014.03.001_bib0045","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1183\/09031936.00001307","article-title":"125\u00a0years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is \u201cscience\u201d enough to tackle the epidemic?","volume":"29","author":"Migliori","year":"2007","journal-title":"Eur Respir J"},{"issue":"20","key":"10.1016\/j.pharma.2014.03.001_bib0050","article-title":"First tuberculosis cases in Italy resistant to all tested drugs","volume":"12","author":"Migliori","year":"2007","journal-title":"Euro Surveill"},{"key":"10.1016\/j.pharma.2014.03.001_bib0055","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3201\/eid1305.060200","article-title":"Extensively drug-resistant tuberculosis, Italy and Germany","volume":"13","author":"Migliori","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.pharma.2014.03.001_bib0060","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1378\/chest.08-2427","article-title":"Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis of totally drug-resistant strain in Iran","volume":"136","author":"Velayati","year":"2009","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.pharma.2014.03.001_bib0065","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1128\/AAC.00106-09","article-title":"Safety, tolerability and pharmacokinetics of PA-824\u00a0in healthy subjects","volume":"53","author":"Ginsberg","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"6789","key":"10.1016\/j.pharma.2014.03.001_bib0070","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/35016103","article-title":"A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis","volume":"405","author":"Stover","year":"2000","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharma.2014.03.001_bib0075","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/jac\/dki319","article-title":"Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines","volume":"56","author":"Protopopova","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.pharma.2014.03.001_bib0080","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/jac\/dkl227","article-title":"Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro","volume":"58","author":"Chen","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.pharma.2014.03.001_bib0085","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/sj.bjp.0705984","article-title":"Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug","volume":"144","author":"Jia","year":"2009","journal-title":"Br J Pharmacol"},{"issue":"5928","key":"10.1016\/j.pharma.2014.03.001_bib0090","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.1171583","article-title":"Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis","volume":"324","author":"Makarov","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.pharma.2014.03.001_bib0100","unstructured":"H37Rv-voir: http:\/\/www.newtbdrugs.org\/project.php?id=145554#sthash.SuQWIbE3.dpuf."},{"year":"2013","series-title":"The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance","author":"World Health Organization","key":"10.1016\/j.pharma.2014.03.001_bib0105"},{"key":"10.1016\/j.pharma.2014.03.001_bib0110","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.apradiso.2010.07.001","article-title":"GMP-compliant automated synthesis of [18F]AV-45 (Florbetapir F 18) for imaging @b-amyloid plaques in human brain","volume":"68","author":"Yao","year":"2010","journal-title":"Appl Radiat Isot"},{"issue":"11","key":"10.1016\/j.pharma.2014.03.001_bib0115","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2967\/jnumed.109.065284","article-title":"Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain","volume":"50","author":"Choi","year":"2009","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.pharma.2014.03.001_bib0120","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2967\/jnumed.109.069088","article-title":"In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18)","volume":"51","author":"Wong","year":"2010","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.pharma.2014.03.001_bib0125","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.2008","article-title":"Use of florbetapir-PET for imaging beta-amyloid pathology","volume":"305","author":"Clark","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.pharma.2014.03.001_bib0130","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00259-011-2021-8","article-title":"Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment","volume":"39","author":"Camus","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"16","key":"10.1016\/j.pharma.2014.03.001_bib0135","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1212\/WNL.0b013e3182661f74","article-title":"Amyloid-(assessed by florbetapir F 18\u00a0PET and 18-month cognitive decline: a multicenter study","volume":"79","author":"Doraiswamy","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pharma.2014.03.001_bib0140","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/WAD.0b013e318279d02a","article-title":"Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline","volume":"27","author":"Grundman","year":"2013","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"24","key":"10.1016\/j.pharma.2014.03.001_bib0145","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1056\/NEJMc0708819","article-title":"Propranolol for severe hemangiomas of infancy","volume":"358","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pharma.2014.03.001_bib0150","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1542\/peds.2008-3458","article-title":"Propranolol for severe infantile hemangiomas: follow-up report","volume":"124","author":"Sans","year":"2009","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.pharma.2014.03.001_bib0155","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaad.2010.12.040","article-title":"Propranolol for treatment of ulcerated infantile hemangiomas","volume":"64","author":"Saint-Jean","year":"2011","journal-title":"J Am Acad Dermat"},{"issue":"1","key":"10.1016\/j.pharma.2014.03.001_bib0160","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/bjd.12217","article-title":"Double-blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants<4\u00a0months of age","volume":"169","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2013","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.pharma.2014.03.001_bib0165","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.arcped.2013.01.052","article-title":"Infantile hemangioma: update and treatment","volume":"20","author":"L\u00e9aut\u00e9-labr\u00e8ze","year":"2013","journal-title":"Arch Pediatr"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000345091400025X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000345091400025X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:31:13Z","timestamp":1757719873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000345091400025X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S000345091400025X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2014.03.001","relation":{},"ISSN":["0003-4509"],"issn-type":[{"type":"print","value":"0003-4509"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c0 propos des ivacaftor, b\u00e9daquiline, florb\u00e9tapir F18\u00a0et propranolol","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2014.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}